June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
TWIN : Evolution of visual acuity in patients with wet AMD diagnosed since 2010 and treated with ranibizumab, in current practice - Comparison with LUMIERE study
Author Affiliations & Notes
  • Hassiba Oubraham Mebroukine
    Office, Montargis, France
  • Salomon Cohen
    Private practice, Paris, France
  • Gerard Mimoun
    Private practice, Paris, France
  • Eric Souied
    Hospital, Creteil, France
  • Stéphane Quéré
    Pharmaceutical industry, Rueil Malmaison, France
  • Véronique Schneider
    Pharmaceutical industry, Rueil Malmaison, France
  • Footnotes
    Commercial Relationships Hassiba Oubraham Mebroukine, Novartis (R); Salomon Cohen, Novartis (C), Allergan (C), Bayer (C), Thea (C), Bausch and Lomb (C); Gerard Mimoun, None; Eric Souied, BAUSCH + LOMB (C), NOVARTIS (C), BAYER (C), THEA (C), ALLERGAN (C); Stéphane Quéré, Novartis Pharma SAS (E); Véronique Schneider, Novartis (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 3821. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hassiba Oubraham Mebroukine, Salomon Cohen, Gerard Mimoun, Eric Souied, Stéphane Quéré, Véronique Schneider, TWIN study group; TWIN : Evolution of visual acuity in patients with wet AMD diagnosed since 2010 and treated with ranibizumab, in current practice - Comparison with LUMIERE study. Invest. Ophthalmol. Vis. Sci. 2013;54(15):3821.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: A previous retrospective study (LUMIERE ) performed with 551 patients diagnosed and treated between 2007 and 2009 has suggested infrequent monitoring explaining why the visual function results were lower. The TWIN study was performed in the same centers to describe the evolution of visual acuity (VA) in patients with wet age-related macular degeneration (wAMD) diagnosed and treated since 2010.

Methods: Retrospective observational study sponsored by Novartis. 21 sites (included 13 of the 16 involved in LUMIERE) included 906 eyes of consecutive patients with wAMD diagnosed and treated since 2010 (from 01-2010 to 11-2011).

Results: In the TWIN study at baseline, most patients were female (67.7%), their mean age was 79.3 ± 7.8 years and their VA 56.8 ± 18.0 letters. The lesion was mostly occult (61.3%). The time from diagnosis to treatment improved from 12.6 ± 26.4 days to 7.7 ± 10.9 days. More patients received an induction phase with the first 3 injections every 4-5 weeks (56.6% vs 39.6% ). No patient had a strict monthly monitoring over 12 months (visits every 30 days +/- 7 days) but about the same proportion of patients underwent "regular" monitoring visits every 37 days +/- 14 days (6.5% vs 4.4%). The average visits number was lower (7.4 ± 2.0 vs 8.6 ± 2.0 ) for a greater average of injections (5.6 ± 2.3 vs 5.1 ± 2.1 injections ). At 12 months, the VA gain was similar (4.3 ± 15.4 vs. 3.2 ± 14.8 letters), but a greater proportion of patients presented a gain greater than 5 letters (43.7% vs 37.0% ) or between 0 and 15 letters (40.2 % vs 33.4% ).

Conclusions: The results suggest that compared to 2007-2009 (LUMIERE), physicians in the TWIN study achieve more VA gainers by waiting less before first treatment and by complying more to the loading doses while monitoring less but giving more injections.

Keywords: 412 age-related macular degeneration  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.